WASHINGTON — Three years after Martin Shkreli became the poster boy of pharmaceutical company greed, another drug company executive is setting himself up for a similar infamy. And now, just as then, there is little the government can do — besides make a fuss.
Nirmal Mulye, CEO of Nostrum Laboratories, quadrupled the price of a generic liquid antibiotic used to treat bladder infections, the Financial Times reported Tuesday. And he had little shame.
“I think it is a moral requirement to make money when you can … to sell the product for the highest price,” Mulye told the FT.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Authors Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect